BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
BIOCRYST PHARMACEUTICALS INC revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORLADEYO | $158.20M | $148.35M | $151.68M | $159.08M | $156.84M | $134.24M | $124.19M | $116.32M | $108.29M | $88.87M | $90.88M | $85.68M | 72.5% | +0.9% |
| Product sales, net | $157.51M | $151.40M | $159.20M | $157.74M | $162.43M | $143.79M | $129.34M | $116.07M | $107.99M | $89.27M | $90.74M | $85.29M | 72.2% | -3.0% |
| License and other revenues | $60.74M | $5.01M | – | – | $923.00K | $1.75M | – | – | – | – | – | – | 27.8% | +6480.4% |
| License and other revenues | $60.05M | – | – | – | $6.52M | – | – | – | – | – | – | – | 27.5% | +821.5% |
| Collaborative and other revenues | – | $2.00M | $3.38M | $1.66M | $923.00K | $1.75M | $2.19M | $1.02M | $1.35M | $3.49M | $2.66M | $1.45M | – | – |
| Other revenues | – | $5.05M | $10.89M | $318.00K | $6.52M | $11.29M | $7.35M | $766.00K | $1.04M | $3.89M | $2.52M | $1.06M | – | – |
| License and other revenues | – | $3.02M | – | – | – | $0 | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Biocryst Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.